| Business Summary | | Cypress
Bioscience
Inc.
is
focused
on
the
development
of
therapeutics
for
the
treatment
of
rheumatologic
disorders
and
has
begun
a
program
directed
at
the
development
of
drug
candidates
for
the
treatment
of
fibromyalgia,
a
chronic
pain
condition.
In
addition,
the
Company
has
evaluated
various
possible
strategic
transactions,
including
the
potential
acquisitions
of
products,
technologies
and
companies,
and
expects
to
continue
to
do
so
in
the
future.
The
Company
is
also
continuing
to
develop
Cyplex,
a
platelet
alternative,
as
an
alternative
to
traditional
platelet
transfusions. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Cypress
Bioscience
researches,
develops,
manufactures
and
markets
medical
devices
and
therapeutics
for
the
treatment
of
immune
disorders
and
develops
therapeutic
agents
for
the
treatment
of
blood
platelet
disorders.
For
the
six
months
ended
6/30/01,
total
revenues
fell
43%
to
$800
thousand.
Net
loss
fell
58%
to
$2.1
million.
Revenues
reflect
the
absence
of
reimbursement
from
Fresenius.
Lower
loss
reflects
the
absence
of
a
$3.6
million
selling
and
marketing
expenses. | More
from
Market Guide: Significant
Developments |
| | | | FY2000 Pay | |
| Jay Kranzler, M.D., Ph.D., 43 Chairman,
CEO, Chief Financial Officer | $664K | John Bonfiglio, 46 Exec.
VP, COO | -- | R. Michael Gendreau, M.D., Ph.D., 46 Exec.
VP, R&D, CMO & Chief Scientific Officer | 382K | Sabrina Johnson, 35 VP
of Marketing | 111K | Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|